share_log

6-K: Gepotidacin Accepted for Priority Review by Us Fda for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

6-K: Gepotidacin Accepted for Priority Review by Us Fda for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

6-K:Gepotidacin用于治疗女性成人和青少年单纯性尿路感染获得美国FDA优先审查
美股SEC公告 ·  10/16 06:27
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息